Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$42.3 million.

  • UroGen Pharma's Cash from Operations fell 5279.79% to -$42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$137.7 million, marking a year-over-year decrease of 4326.37%. This contributed to the annual value of -$96.8 million for FY2024, which is 2669.69% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Cash from Operations is -$42.3 million, which was down 5279.79% from -$39.8 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Cash from Operations ranged from a high of -$13.0 million in Q4 2023 and a low of -$42.3 million during Q3 2025
  • Its 5-year average for Cash from Operations is -$24.7 million, with a median of -$23.7 million in 2024.
  • As far as peak fluctuations go, UroGen Pharma's Cash from Operations soared by 4025.38% in 2023, and later tumbled by 6769.83% in 2025.
  • Quarter analysis of 5 years shows UroGen Pharma's Cash from Operations stood at -$20.1 million in 2021, then decreased by 8.38% to -$21.8 million in 2022, then soared by 40.25% to -$13.0 million in 2023, then decreased by 4.79% to -$13.6 million in 2024, then tumbled by 210.38% to -$42.3 million in 2025.
  • Its Cash from Operations was -$42.3 million in Q3 2025, compared to -$39.8 million in Q2 2025 and -$42.0 million in Q1 2025.